Royal Sense Limited (RSL) has taken a significant step forward in its proposed merger with TTG Innovations Private Limited (TIPL). The company recently received a no-adverse observation letter from the BSE Limited, paving the way for the next phase of the merger process.

Key Details of the BSE Observation Letter

• Date of Issuance: November 19, 2025
• Validity Period: Six months from the date of issuance
• Purpose: Enables Royal Sense Limited to file the merger scheme with NCLT
• Conditions: Subject to compliance with 15 specific conditions

Merger Scheme Overview

The proposed merger scheme involves the absorption of TTG Innovations Private Limited (Transferor Company) into Royal Sense Limited (Transferee Company). This corporate action falls under sections 230 to 232 of the Companies Act, 2013, and is subject to various regulatory approvals.

Timeline of Events

Compliance Requirements

The BSE's no-adverse observation letter comes with specific conditions that Royal Sense Limited must adhere to:

1. Disclosure requirements as per regulatory provisions
2. Compliance with 15 specific conditions (details not provided in the available information)

Next Steps

With the BSE's no-adverse observation letter in hand, Royal Sense Limited is now positioned to proceed with filing the merger scheme with the National Company Law Tribunal (NCLT). This marks a crucial milestone in the merger process between Royal Sense Limited and TTG Innovations Private Limited.

The company's management will need to ensure strict compliance with the conditions set forth by the BSE as they move forward with the merger proceedings.

Investors and stakeholders of Royal Sense Limited should keep a close watch on further developments related to this merger, as it may have implications for the company's future operations and market position.

Royal Sense Limited has announced the launch of its new franchise business model, 'Stergic Pharmacy', marking a significant step in the company's growth strategy. The initiative, revealed in a regulatory filing dated August 12, 2025, aims to establish a network of franchise-owned and company-operated (FOCO) retail stores across India.

Franchise Model Details

The 'Stergic Pharmacy' concept is designed to offer over 500 products through franchise-based retail outlets. This move represents Royal Sense's strategic approach to expand its presence in the pharmaceutical retail sector while leveraging the local expertise of franchise partners.

Strong Initial Interest

According to the company's disclosure, the launch has already garnered substantial interest from potential franchisees. Royal Sense has received more than 125 franchise applications, highlighting the attractiveness of the business model. The company is currently evaluating these applications to select candidates who align best with its strategic objectives and quality standards.

Management's Perspective

Rishabh Arora, Managing Director of Royal Sense Limited, signed the regulatory filing, underscoring the importance of this initiative. The company views the 'Stergic Pharmacy' franchise model as a significant growth opportunity, potentially accelerating its expansion in the competitive pharmaceutical retail market.

Future Outlook

Royal Sense Limited has committed to providing updates to the stock exchanges and stakeholders as further developments occur. The company's focus on careful selection of franchise partners suggests a strategic approach to ensure the quality and consistency of the 'Stergic Pharmacy' brand across various locations.

This new venture represents a notable development in the Indian pharmaceutical retail landscape, potentially offering investors and stakeholders a new avenue for growth. As Royal Sense progresses with its franchise model, market observers will be keen to see how it impacts the company's market position and financial performance in the coming quarters.